Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries

Respirology

Volumn 13, Issue 1, 2008, Pages 47-52

  Huang, Heng Ching ^b   Shieh, Chi Chang ^c   Yu, Wen Liang ^b   Cheng, Kuo Chen ^b   Chen, Chi Chung ^b   Chang, Sheng Tsung ^b   Chuang, Yin Ching ^a,b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Acute lung injury; Cytokine; Fluoroquinolone; Lipopolysaccharide

Indexed keywords

CIPROFLOXACIN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEVOFLOXACIN; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 2; MOXIFLOXACIN; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME;

ANIMALS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; CYTOKINES; DISEASE MODELS, ANIMAL; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; OFLOXACIN; QUINOLINES; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 38049153047     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2007.01192.x     Document Type: Article

References (33)

1. Zilberberg MD, Epstein SK. Acute lung injury in the medical ICU: comorbid conditions, age, etiology, and hospital outcome. Am. J. Respir. Crit. Care Med. 1998 157 : 1159 64.
2. Sloane PJ, Gee MH, Gottlieb JE, Albertine KH, Peters SP et al. A multicenter registry of patients with acute respiratory distress syndrome. Physiology and outcome. Am. Rev. Respir. Dis. 1992 146 : 419 26.
3. Doyle RL, Szaflarski N, Modin GW, Wiener-Kronish JP, Matthay MA et al. Identification of patients with acute lung injury. Predictors of mortality. Am. J. Respir. Crit. Care Med. 1995 152 : 1818 24.
4. Pittet JF, Mackersie RC, Martin TR, Matthay MA. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am. J. Respir. Crit. Care Med. 1997 155 : 1187 205.
5. Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J. Pathol. 2004 202 : 145 56.
6. Bailly S, Ferrua B, Fay M, Gougerot-Pocidalo MA. Differential regulation of IL 6, IL 1 A, IL 1 beta and TNF alpha production in LPS-stimulated human monocytes: role of cyclic AMP. Cytokine 1990 2 : 205 10.
7. Bailly S, Fay M, Ferrua B, Gougerot-Pocidalo MA. Ciprofloxacin treatment in vivo increases the ex vivo capacity of lipopolysaccharide-stimulated human monocytes to produce IL-1, IL-6 and tumour necrosis factor-alpha. Clin. Exp. Immunol. 1991 85 : 331 4.
8. Shalit I. Immunological aspects of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 1991 10 : 262 6.
9. Stunkel KG, Hewlett G, Zeiler HJ. Ciprofloxacin enhances T cell function by modulating interleukin activities. Clin. Exp. Immunol. 1991 86 : 525 31.
10. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 2001 163 : 1730 54.
11. Anonymous. Guidelines for the management of adults with hospital-acquired, ventilator-associated, health care-associated pneumonia. Am. J. Respir. Crit. Care Med. 2005 171 : 388 416.
12. Yoshimura T, Kurita C, Usami E, Nakao T, Watanabe S et al. Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells. Chemotherapy 1996 42 : 459 64.
13. Araujo FG, Slifer TL, Remington JS. Effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide. Clin. Microbiol. Infect. 2002 8 : 26 30.
14. Ho W, Furst A. Intratracheal instillation method for mouse lungs. Oncology 1973 27 : 385 93.
15. Tulic MK, Wale JL, Holt PG, Sly PD. Differential effects of nitric oxide synthase inhibitors in an in vivo allergic rat model. Eur. Respir. J. 2000 15 : 870 7.
16. Riesbeck K, Forsgren A. Increased interleukin 2 transcription in murine lymphocytes by ciprofloxacin. Immunopharmacology 1994 27 : 155 64.
17. Purswani MU, Eckert SJ, Arora HK, Noel GJ. Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine responses in a murine in vivo model. J. Antimicrob. Chemother. 2002 50 : 51 8.
18. Yamashita Y, Ashizawa T, Morimoto M, Hosmomi J, Nakano H. Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity. Cancer Res. 1992 52 : 2818 22.
19. Shalit I, Kletter Y, Weiss K, Gruss T, Fabian I. Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones. Eur. J. Haematol. 1997 58 : 92 8.
20. Katsuno G, Takahashi HK, Iwagaki H, Sugita S, Mori S et al. The effect of ciprofloxacin on CD14 and Toll-like receptor-4 expression on human monocytes. Shock 2006 25 : 247 53.
21. Weber S, Shalit I, Fabrian I, Steuer G, Weiss T et al. Moxifloxacin inhibits cytokine-induced MAP kinase and NF-κB activation as well as nitric oxide synthesis in a human respiratory epithelial cell line. J. Antimicrob. Chemother. 2005 55 : 293 300.
22. Khan AA, Slifer TR, Araujo FG, Suzuki Y, Remington JS. Protection against lipopolysaccharide-induced death by fluoroquinolones. Antimicrob. Agents Chemother. 2000 44 : 3169 73.
23. Purswani M, Eckert S, Arora H, Johann-Liang R, Noel GJ. The effect of three broad-spectrum antimicrobials on mononuclear cell responses to encapsulated bacteria: evidence for down-regulation of cytokine mRNA transcription by trovafloxacin. J. Antimicrob. Chemother. 2000 46 : 921 9.
24. Shalit I, Horev-Azaria L, Fabian I, Blau H, Kariv N et al. Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide. Antimicrob. AgentsChemother. 2002 46 : 2442 9.
25. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect. Dis. 2003 3 : 359 71.
26. Nwariaku FE, McIntyre KL, Sikes PJ, Mileski NJ. The effect of antimicrobial agents on the induction of tumor necrosis factors by alveolar macrophages in vitro response to endotoxin. J. Antimicrob. Chemother. 1997 39 : 265 7.
27. Driscoll KE, Hassenbein DG, Carter JM, Kunkel SL, Quinlan TR et al. TNF alpha and increased chemokine expression in rat lung after particle exposure. Toxicol. Lett. 1995 82-83 : 483 9.
28. Gupta S, Feng L, Yoshimura T, Redick J, Fu SM. Intra-alveolar macrophage-inflammatory peptide 2 induces rapid neutrophil localization in the lung. Am. J. Respir. Cell Mol. Biol. 1996 15 : 656 63.
29. Shanley TP, Vasi N, Denenberg A. Regulation of chemokine expression by IL-10 in lung inflammation. Cytokine 2000 12 : 1054 64.
30. Kalyanaraman M, Heidemann SM, Sarnaik AP. Macrophage inflammatory protein-2 predicts acute lung injury in endotoxemia. J. Investig. Med. 1998 46 : 275 8.
31. Parnham MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr. Opin. Infect. Dis. 2005 18 : 125 31.
32. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004 125 : 41S 51S.
33. Amsden GW. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J. Antimicrob. Chemother. 2005 55 : 10 21.